Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4D-150 Gene Therapy in Diabetic Macular Edema (SPECTRA)
NCT05930561Phase 2Active, not recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Aug 2023
- Primary completion
- Feb 2029
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of 4D-150 in diabetic macular edema (DME), diabetic retinopathy (DR), sponsored by 4D Molecular Therapeutics. Started Aug 2023; status: active, not recruiting.
02
Drugs
4D-150
03
Conditions
diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05930561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930561.